2016 American Transplant Congress
Impact of HLA-DR Compatibility on Efficacy Outcomes and Renal Function in Kidney Transplant Recipients Following Early Switch from Calcineurin Inhibitor to Everolimus: Subanalysis from the ELEVATE Study.
ELEVATE study group, Llobregat Catalunya, Spain.
Background: Human leukocyte antigen (HLA) compatibility between donor and recipient is considered an important factor for graft outcomes. Compatibility is associated with a lower incidence…2016 American Transplant Congress
Prospective Randomized Controlled Study Evaluating the Impact of an Electronic Feedback System on Medication Adherence in Solid Organ Transplantation.
University of Chicago Transplant Center, University of Chicago, Chicago.
Purpose: To evaluate the impact of and electronic feedback system (EFS), SIMpill Medication Adherence System®, on medication adherence in patients who have received a solid…2016 American Transplant Congress
Evaluation According to Donor Source: 24-Month Results from Post-Hoc Analysis of the ELEVATE Study in Kidney Transplant Recipients.
ELEVATE study group, Leiden, Netherlands.
Background: Several studies reported that recipients receiving renal allograft from living donors have better efficacy outcomes than the deceased donor counterparts. This post-hoc analysis of…2016 American Transplant Congress
Hepatocellular Carcinoma Decreases Chance of Successful HCV Therapy in the Current Era.
Gastroenterology and Hepatology, Northwestern University, Chicago, IL.
Background: The efficacy of direct acting antiviral agents (DAA) for hepatitis C (HCV) in patients with hepatocellular carcinoma (HCC) is limited. We hypothesized that virology…2016 American Transplant Congress
The BEST Trial: A Prospective Randomized Trial of Belatacept-Based, CNI- and Corticosteroid-Free Immunosuppression.
Efficacy of CNI- and corticosteroid-free immunosuppressive regimens has not been demonstrated in large, multicenter trials. BEST (Belatacept-based Early Steroid Withdrawal Trial) (NCT 01729494) compares 2…2016 American Transplant Congress
Impact of Early Calcineurin Inhibitor Withdrawal on Renal Function and Urinary Protein Excretion: 24 Month Analyses of the ELEVATE Study.
Background: Proteinuria is a biomarker which helps in predicting graft outcomes in kidney transplant recipients (KTxRs). The ELEVATE study was designed to determine whether an…2016 American Transplant Congress
TRANSFORM: A Modern Approach to Evaluate Long-Term Outcomes of Everolimus with Reduced-Calcineurin Inhibitors in De Novo Kidney Transplant Recipients[mdash]Baseline Characteristics.
Purpose: Acute rejection and poor graft function are two major risk factors for allograft failure in kidney transplant (KTx) recipients (KTxR). Although, graft survival and…2016 American Transplant Congress
Relationship Between Clinical Events and Everolimus Exposure at 12 Months in De Novo Renal Transplant Recipients.
We assessed the incidence of post-transplant biopsy-proven acute rejection (BPAR), graft loss and other adverse events (AEs) associated with everolimus (EVR) and tacrolimus (TAC) exposure…2016 American Transplant Congress
Induction with T-cell Depletional Agents Is Safe and Efficacious in the Very Elderly Kidney Transplant Recipients: An Analysis of the OPTN Database.
Virginia Commonwealth University, Richmond, VA.
Background: Kidney transplantation is increasingly being offered to the very elderly (Age>70 years) kidney transplant recipients. Previous studies analyzing the effect of induction immunosuppression in…2016 American Transplant Congress
Evaluation of the Long-Term Outcomes with Everolimus After Calcineurin Inhibitor Withdrawal: 36M Results of the H2304 and PROTECT Extension Studies.
Background: The H2304 and PROTECT studies demonstrated reduced nephrotoxicity with everolimus (EVR)-based calcineurin inhibitor (CNI; cyclosporine: CsA, tacrolimus: TAC)-free regimens at Month (M) 12. Here,…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- 14
- Next Page »